Log in

NASDAQ:INMDInMode Stock Price, Forecast & News

$31.77
+0.73 (+2.35 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$30.77
Now: $31.77
$32.20
50-Day Range
$25.82
MA: $30.73
$35.60
52-Week Range
$13.06
Now: $31.77
$58.76
Volume320,208 shs
Average Volume910,765 shs
Market Capitalization$1.02 billion
P/E Ratio25.62
Dividend YieldN/A
BetaN/A
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. InMode Ltd. offers its products directly in the United States, Canada, the United Kingdom, Spain, and India, as well as indirectly through third-party distributors internationally. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.76 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INMD
CUSIPN/A
Phone972-4909-6313

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$156.36 million
Cash Flow$1.92 per share
Book Value$6.42 per share

Profitability

Net Income$61.15 million

Miscellaneous

Employees198
Market Cap$1.02 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableNot Optionable
$31.77
+0.73 (+2.35 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INMD News and Ratings via Email

Sign-up to receive the latest news and ratings for INMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











InMode (NASDAQ:INMD) Frequently Asked Questions

How has InMode's stock been impacted by COVID-19 (Coronavirus)?

InMode's stock was trading at $24.40 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INMD shares have increased by 30.2% and is now trading at $31.77.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of InMode?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InMode in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for InMode
.

When is InMode's next earnings date?

InMode is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for InMode
.

How were InMode's earnings last quarter?

InMode Ltd. (NASDAQ:INMD) issued its quarterly earnings results on Wednesday, August, 5th. The healthcare company reported $0.21 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.22) by $0.43. The healthcare company had revenue of $30.80 million for the quarter, compared to analysts' expectations of $30.41 million. InMode had a net margin of 31.76% and a return on equity of 27.15%. The business's revenue for the quarter was down 20.6% compared to the same quarter last year.
View InMode's earnings history
.

What guidance has InMode issued on next quarter's earnings?

InMode issued an update on its FY 2020 Pre-Market earnings guidance on Wednesday, August, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $156-160 million, compared to the consensus revenue estimate of $143.04 million.

What price target have analysts set for INMD?

4 Wall Street analysts have issued 12 month target prices for InMode's shares. Their forecasts range from $36.00 to $55.00. On average, they anticipate InMode's stock price to reach $43.25 in the next year. This suggests a possible upside of 36.1% from the stock's current price.
View analysts' price targets for InMode
.

Has InMode been receiving favorable news coverage?

Media stories about INMD stock have been trending somewhat positive on Sunday, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. InMode earned a news impact score of 1.3 on InfoTrie's scale. They also assigned news coverage about the healthcare company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days.
View the latest news about InMode
.

Who are some of InMode's key competitors?

What other stocks do shareholders of InMode own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InMode investors own include NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), salesforce.com (CRM), Trade Desk (TTD), AbbVie (ABBV), Alteryx (AYX), Micron Technology (MU), Okta (OKTA) and Square (SQ).

Who are InMode's key executives?

InMode's management team includes the following people:
  • Mr. Moshe Mizrahy, Chairman & CEO (Age 66)
  • Mr. Yair Malca, Chief Financial Officer (Age 41)
  • Dr. Michael Kreindel, CTO & Director (Age 51)
  • Mr. Shakil Lakhani, Pres of North America (Age 35)
  • Dr. Spero Theodorou, Chief Medical Officer (Age 47)

When did InMode IPO?

(INMD) raised $75 million in an IPO on Thursday, August 8th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. ​Barclays, UBS Investment Bank and Canaccord Genuity acted as the underwriters for the IPO and Baird was co-manager.

What is InMode's stock symbol?

InMode trades on the NASDAQ under the ticker symbol "INMD."

Who are InMode's major shareholders?

InMode's stock is owned by a variety of institutional and retail investors. Top institutional investors include UBS Group AG (0.46%), Hodges Capital Management Inc. (0.39%), Taylor Frigon Capital Management LLC (0.32%), Roubaix Capital LLC (0.17%), SG Americas Securities LLC (0.13%) and Virtu Financial LLC (0.12%).

Which major investors are selling InMode stock?

INMD stock was sold by a variety of institutional investors in the last quarter, including US Bancorp DE, Jacobi Capital Management LLC, and Raymond James Financial Services Advisors Inc..

Which major investors are buying InMode stock?

INMD stock was acquired by a variety of institutional investors in the last quarter, including Hodges Capital Management Inc., Taylor Frigon Capital Management LLC, UBS Group AG, Virtu Financial LLC, SG Americas Securities LLC, Swiss National Bank, Envestnet Asset Management Inc., and Bfsg LLC.

How do I buy shares of InMode?

Shares of INMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is InMode's stock price today?

One share of INMD stock can currently be purchased for approximately $31.77.

How big of a company is InMode?

InMode has a market capitalization of $1.02 billion and generates $156.36 million in revenue each year. The healthcare company earns $61.15 million in net income (profit) each year or $1.60 on an earnings per share basis. InMode employs 198 workers across the globe.

What is InMode's official website?

The official website for InMode is www.inmodemd.com.

How can I contact InMode?

InMode's mailing address is TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200. The healthcare company can be reached via phone at 972-4909-6313 or via email at [email protected]

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.